Munich-based healthtech firm CollimateHealth has secured €6 million in seed funding from VP Venture Partners, Positron, XISTA Science Ventures, caesar, and High-Tech Gründerfonds (HTGF).
- Founded in 2024 by Prof. Dr. Stefan Bartzsch, Dr. Johanna Winter and Dr. Hans Maria Heÿn, CollimateHealth is developing microbeam radiation therapy that uses arrays of micrometre-scale beams delivered at high peak doses to target tumours more precisely than conventional broad-beam radiation, with the aim of reducing damage to surrounding healthy tissue.
- The approach is also being explored for its potential to stimulate anti-tumour immune responses through increased antigen presentation and to improve drug delivery by creating temporary microchannels within tumour tissue, which could enhance the impact of chemotherapy and immunotherapy.
- The technology has been developed over nearly a decade in collaboration with the Technical University of Munich (TUM), The Royal Marsden Hospital and the Institute of Cancer Research. The company is now progressing towards a first clinical prototype, with initial patient use targeted for 2028.
Details of the deal
- The aim of the €6 million seed round is to fund CollimateHealth’s development of a first clinical prototype of its microbeam radiation therapy system, generate the necessary preclinical data for regulatory approval, and progress toward treating the first patients within the next three years.
“CollimateHealth is exactly the kind of DeepTech venture HTGF was founded to support: a world-class scientific team translating years of rigorous research into a technology that could genuinely change outcomes for cancer patients. What excites us most is not just the physics, but the clinical ambition. The team has a clear path to first-patient use, and we are proud to back them on that journey," explains Dr Jan Engels, Senior Investment Manager at HTGF.
